Mesoblast Limited is an Australian-based regenerative medicine company, founded in 2004. It provides treatments for inflammatory ailments, cardiovascular disease and back pain. Using financial statement data of 2018 and 2019 , compute the Altman Z-score value for Mesoblast for 2018 and 2019. Do you think the Altman Z-score works well for firms like Mesoblast? Why?

All values in millions	2018	2019
Sales	21.91	22.38
EBIT	-98.56	-113.08
Current Assets	136.80	89.09
Current Liabilities	32.69	63.31
Total Assets	1,013.76	1,022.51
Total Liabilities	274.76	337.00
Total Shareholders' Equity	-98.56	-113.08
Total Shares Outstanding	479.14	495.13
Retained Earnings	-514.57	-669.74
Stock Price per Share	1.54	1.38